Cinobufotalin reduces glioblastoma resistance to temozolomide by inhibiting the CCL5-mediated PI3K/Akt/mTOR signaling pathway
{{output}}
Background: Temozolomide (TMZ) resistance is a key factor that restricts the therapeutic effects of glioblastoma (GBM). The pharmacological properties of cinobufotalin (CB) indicated that CB promotes the cell death of GBM cells, ... ...
